Extending anti-VEGF intervals while maintaining efficacy may depend more on individual patients than the treatment agent or dose, according to a presenter at OSN New York Retina.
“Dosing frequencies may be more about the individual patient factors than anti-VEGF agent or dose level administered,” Jorge A. Fortun, MD, of Bascom Palmer Eye Institute, said.
In a cross-trial comparison of marketed anti-VEGF therapies for neovascular age-related macular degeneration, more than 50% of patients on a true quarterly dosing regimen maintained or gained vision by the end of the trial, Fortun
Uncategorized